Interaction of human papillomaviruses with the host immune system: a well evolved relationship. (Q37318349)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

Interaction of human papillomaviruses with the host immune system: a well evolved relationship (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Ian H Frazer

1 reference

19 August 2017

language of work or name

English

0 references

publication date

4 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

19 August 2017

volume

384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

410-414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18986661%20AND%20SRC:MED&resulttype=core&format=json

Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Down-regulation of MHC class I is a property common to papillomavirus E5 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Anaphylaxis following quadrivalent human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

HPV-1 Capsids Expressed in Vitro Detect Human Serum Antibodies Associated with Foot Warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Immunological events in regressing genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

WHIM syndrome: a defect in CXCR4 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

The papillomavirus life cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Prevention of cervical cancer through papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

WHIM syndrome: a genetic disorder of leukocyte trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Long-lasting response of therapy-resistant viral warts to treatment with interleukin-2 in a patient with chronic lymphocytic leukemia (CLL) and profound immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Familial risks for cervical tumors in full and half siblings: etiologic apportioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Cell-mediated immune responses to COPV early proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Papillomavirus vaccines in perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Evolving immunosuppressive microenvironment during human cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Autosomal-dominant primary immunodeficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Prophylactic human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

A call to arms: coevolution of animal viruses and host innate immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Generalized warts and immune deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Skin infections in organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Idiopathic Late-Onset Immunoglobulin Deficiency With Functional T-Cell Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004

Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.10.004